With 96 Percent Opt-In Rate, Actos Bladder Cancer Settlement Gets $2.37B Payment
DEERFIELD, Ill. — Takeda Pharmaceutical Co. Ltd. on Sept. 12 announced that more than 96 percent of eligible claimants have opted in to the $2.4 billion Actos bladder cancer settlement, triggering...To view the full article, register now.
Already a subscriber? Click here to view full article